User profiles for B. D. Hamman
 | Brian HammanHotSpot Therapeutics, Arvinas Inc., Lexicon Pharmaceuticals, Vertex Pharma. Verified email at hotspotthera.com Cited by 4504 |
[PDF][PDF] Lessons in PROTAC design from selective degradation with a promiscuous warhead
…, J Hines, S Jaime-Figueroa, J Wang, BD Hamman… - Cell chemical …, 2018 - cell.com
Inhibiting protein function selectively is a major goal of modern drug discovery. Here, we
report a previously understudied benefit of small molecule proteolysis-targeting chimeras (…
report a previously understudied benefit of small molecule proteolysis-targeting chimeras (…
[HTML][HTML] BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation
… Includes data previously reported in Hamman et al. 1997 using wheat germ source “B”; all
… Includes data previously reported in Hamman et al. 1997 using wheat germ source “B”; all …
… Includes data previously reported in Hamman et al. 1997 using wheat germ source “B”; all …
[HTML][HTML] Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
…, A Harbin, J Wang, BD Hamman… - Nature …, 2019 - nature.com
PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit
an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many …
an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many …
Identification of a Membrane-Spanning Domain of the Thiol-Activated Pore-Forming Toxin Clostridium perfringens Perfringolysin O: An α-Helical to β-Sheet …
Clostridium perfringens perfringolysin O (PFO or θ-toxin) is a cytolytic toxin that binds to
cholesterol-containing membranes and then self-associates to spontaneously form aqueous …
cholesterol-containing membranes and then self-associates to spontaneously form aqueous …
[HTML][HTML] The aqueous pore through the translocon has a diameter of 40–60 Å during cotranslational protein translocation at the ER membrane
Eukaryotic secretory proteins are cotranslationally translocated through the endoplasmic
reticulum (ER) membrane via aqueous pores that span the lipid bilayer. Fluorescent probes …
reticulum (ER) membrane via aqueous pores that span the lipid bilayer. Fluorescent probes …
Identification and characterization of Von Hippel-Lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1
…, D Vigil, YV Serebrenik, BD Hamman… - Journal of medicinal …, 2018 - ACS Publications
Proteolysis targeting chimeras (PROTACs) are bifunctional molecules that recruit an E3 ligase
to a target protein to facilitate ubiquitination and subsequent degradation of that protein. …
to a target protein to facilitate ubiquitination and subsequent degradation of that protein. …
A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases
SM Rodems, BD Hamman, C Lin, J Zhao… - Assay and drug …, 2002 - liebertpub.com
Protein phosphorylation is one of the major regulatory mechanisms involved in signal-induced
cellular events, including cell proliferation, apoptosis, and metabolism. Because many …
cellular events, including cell proliferation, apoptosis, and metabolism. Because many …
Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain
W Kostich, BD Hamman, YW Li, S Naidu… - … of Pharmacology and …, 2016 - ASPET
To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute
and persistent pain behavior assays. One of the lines from this screen, which contained a …
and persistent pain behavior assays. One of the lines from this screen, which contained a …
[HTML][HTML] Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
…, X Ye, E Rousseau, T Januario, BD Hamman… - Nature …, 2022 - nature.com
The mammalian SWItch/Sucrose Non-Fermentable (SWI/SNF) helicase SMARCA4 is
frequently mutated in cancer and inactivation results in a cellular dependence on its paralog, …
frequently mutated in cancer and inactivation results in a cellular dependence on its paralog, …
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma
…, K Gu, R Mabon, M Gardyan, BD Hamman… - Journal of medicinal …, 2009 - ACS Publications
The discovery of a pyrrolopyrimidine class of LIM-kinase 2 (LIMK2) inhibitors is reported.
These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good …
These LIMK2 inhibitors show good potency in enzymatic and cellular assays and good …